Skip to main content
Equibles
OVID logo

OVID · Ovid Therapeutics Inc. · Investor Relations

Track OVID — free

Use OVID with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OVID.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.45 +0.08 (+3.38%)
Russell 2000 member Rebalance outlook locked
Market Cap
$468.71M
Shares
195.30M
Volume · Oct 7 396.47K Avg daily vol (3M) 1.63M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-03 Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-08-13 Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
2026-07-08 Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
2026-06-04 Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-06-03 Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
2026-05-12 Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
2026-04-08 Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
2026-03-18 Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-18 Ovid Therapeutics Announces Pricing of $60 Million Private Placement
2026-02-25 Ovid Therapeutics to Participate in Upcoming Investor Conferences
2025-12-18 Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
2025-12-02 Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
2025-11-12 Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Past events

Date Event Type
2026-09-14 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-09 Cantor Global Healthcare Conference Conference
2026-06-15 H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference Conference
2026-04-14 KCC2 Deep Dive R&D Event Event
2026-03-18 Earnings conference call (announced in 8-K) Earnings call
2026-03-09 Leerink Global Healthcare Conference Conference
2026-03-04 TD Cowen 46th Annual Health Care Conference Conference
2026-02-25 Oppenheimer 36th Annual Healthcare Life Sciences Conference Conference
2025-10-03 OV329 topline results webcast from the phase 1 healthy volunteer study Earnings call
2025-06-12 Biomarkers in Epilepsy Investor Event Event
2025-04-07 24th Annual Needham Virtual Healthcare Conference Conference
2025-03-03 TD Cowen 45th Annual Health Care Conference Conference
2025-02-12 Oppenheimer 35th Annual Healthcare Life Sciences Conference Conference
2024-11-13 KCC2 Download Day Event
2024-09-19 2024 Cantor Global Healthcare Conference Conference
2024-09-10 H.C. Wainwright 26th Annual Global Investment Conference Conference
2024-05-20 H.C. Wainwright 2nd Annual BioConnect Investor Conference Conference
2024-04-11 23rd Annual Needham Virtual Healthcare Conference Conference
2024-03-06 TD Cowen 44th Annual Health Care Conference Conference
2024-02-13 Oppenheimer 34th Annual Healthcare Life Sciences Conference Conference
2023-10-12 Jefferies Biotech CNS/Neuro Summit Event
2023-10-02 Ovid R&D Day Event
2023-09-26 2023 Cantor Fitzgerald Global Healthcare Conference Conference
2023-09-12 H.C. Wainwright 25th Annual Global Investment Conference Conference
2023-04-17 22nd Annual Needham Virtual Healthcare Conference Conference

Source: https://investors.ovidrx.com/overview/default.aspx

Key facts CIK 1636651 CUSIP 690469101 13F (30d) 2 filings 2 filers Visit website Investor relations